Ep 58 - Getting to the heart of Boston Scientific’s peripheral business; How Hologic sees trials changing

Jeff Mirviss, executive vice president of Boston Scientific’s peripheral business, explains why the specialty’s name doesn’t really reflect the importance of arteries, veins and other “highways” that his business group is addressing. Mirviss explains where the peripheral business is headed, and why Boston Scientific is uniquely positioned to address the business. He also shares lessons learned over his 20-plus years at Boston Scientific including the challenges presented by the Guidant acquisition and the new spirit infused by CEO Michael Mahoney. We also speak with Eric Kolodziej, corporate vice president and global head quality and regulatory affairs at Hologic, about how clinical trial management is changing. What role will real world evidence play going forward, and how will Hologic and others follow up on the record number of EUA’s issued over the past year by the FDA. Chris Newmarker, executive editor of life sciences at Mass Device, delivers his Newmarker’s Newsmakers bringing news from Medtronic, Abbott, Zimmer Biomet and Shockwave. Pharma Editor Brian Buntz also sits in the virtual booth to talk about the new Pharma 50 report compiled by our editorial team. Subscribe today on most major podcast applications.

There are no comments yet.

Please log in to write the first comment.